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Background. Int-6 (integration site 6) was identified as an oncogene in a screen of tumorigenic mouse mammary tumor virus
(MMTV) insertions. INT6 expression is altered in human cancers, but the precise role of disrupted INT6 in tumorigenesis
remains unclear, and an animal model to study Int-6 physiological function has been lacking. Principal Findings. Here, we
create an in vivo model of Int6 function in zebrafish, and through genetic and chemical-genetic approaches implicate Int6 as
a tissue-specific modulator of MEK-ERK signaling. We find that Int6 is required for normal expression of MEK1 protein in human
cells, and for Erk signaling in zebrafish embryos. Loss of either Int6 or Mek signaling causes defects in craniofacial
development, and Int6 and Erk-signaling have overlapping domains of tissue expression. Significance. Our results provide
new insight into the physiological role of vertebrate Int6, and have implications for the treatment of human tumors displaying
altered INT6 expression.
Citation: Grzmil M, Whiting D, Maule J, Anastasaki C, Amatruda JF, et al (2007) The INT6 Cancer Gene and MEK Signaling Pathways Converge during
Zebrafish Development. PLoS ONE 2(9): e959. doi:10.1371/journal.pone.0000959
INTRODUCTION
Embryonic development and tumour development often share
underlying molecular mechanisms–a concept illustrated by the
identification of genes disrupted by the mouse mammary tumor
virus (MMTV) in mammary cancers [1]. An important example,
the Int-1 gene which is a common integration site for MMTV in
mammary tumours, encodes the homologue of the Drosophila
wingless gene [2,3] and was subsequently named Wnt1 (wingless/
Int) in recognition of this conserved function. Wnt signaling is now
known to be disrupted in many human tumor types, especially
colon cancer [4]. Other Int genes, such as Int-2 and 4 (Fgf3, 4), and
Int-3 (Notch4), encode mitogens and regulators of development
that are also misactivated in many cancers [1,5].
In the majority of cases, MMTV activates Int gene expression as
a result of proviral integration upstream of the promoter region.
Remarkably, all three MMTV insertions found in Int-6, which
encodes a component of the eukaryotic translation initation factor
3 (eIF3), were found to lie within introns, and in the opposite
transcriptional orientation to the Int-6 gene, creating a truncated
Int-6 mRNA [1,6]. Ectopic expression of equivalently truncated
Int-6 can transform cell cultures [7,8], and promote persistent
mammary alveolar hyperplasia and tumorigenesis in transgenic
mice [9].
Despite important evidence in favor of a role for INT6 in
human tumourigenesis [10–12], the molecular basis for INT6
in cancer development remains unresolved. Highly conserved
in eukaryotes, INT6 contains a PCI domain, found in proteins
of the 19S regulatory lid of the proteasome, the COP9
signalosome (CSN), and the eIF3 translation initiation complex;
all three complexes share overall structural similarity, and
INT6 has been found associated with each [13]. When over-
expressed in yeast, Int6 induces multi-drug resistance by activating
an AP-1 transcription factor [14,15], and in human cells, the
range of INT6 function includes orderly progression through
mitosis [16], regulation of the proteasome-dependent stability of
MCM7 [17] and HIF2a [18], and nonsense mediated mRNA
decay [19].
With no animal model for Int6 loss-of-function available, we
reasoned that an understanding of INT6 during development
would provide novel insight into INT6 function in normal
vertebrate cells, thereby providing a new perspective on INT6
function in cancer formation. Here, using zebrafish and
mammalian cells, we describe the first Int6 loss-of-function
phenotype in an animal, and link Int6 with a signaling pathway,
that like those effected by other Int genes, is critical for both
development and cancer.
RESULTS
Int6 is essential for zebrafish embryogenesis
We chose to study the physiological role of zebrafish Int6 during
development, using morpholino oligonucleotides (MOs) to reduce
Int6 protein, as well as an int6
hi2470 insertional mutant line (kindly
provided by N. Hopkins, A. Amsterdam and S. Farrington.
M.I.T.). Zebrafish Int6 is over 90% identical in its amino acid
sequence to human INT6 (Ensembl ENSDARG00000002549) and
using an Int6 antibody raised against the N-terminus of the human
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(Figure 1A). As INT6 has been implicated in G2/M-phase cell
cycle control, we first performed whole-mount immunohistochem-
istry with the late G2/M phase marker, phospho-histone H3, and
found only slightly reduced numbers of cells in late G2/M phase in
the int6 morphant compared to the control (Figure S1).
Importantly, we found that embryos injected with int6 MO had
specific developmental defects (Figure 1B–N), most notably
reduced melanisation 2 days post-fertilization (dpf: int-6 MO
n=51/53; con MO n=0/35; int-6 5MM n=3/31); misplaced
pigment cells in the tail 3 dpf (int-6 MO n=46/49; con MO n=
3/30); and abnormal jaw morphogenesis, with cartilage elements
reduced or malformed at 4 and 5 dpf (int-6 MO n=81/85 4 dpf,
n=76/83 5 dpf; con MO 1/67 4 dpf, n=1/61 5 dpf). The
craniofacial and pigment cell defects observed in the int-6
morphant and hi2470 mutant suggest that int-6 might contribute
to development of neural crest-cell (NCC) derivatives. We used
multiple markers of NCCs and their derivatives to assess when
these phenotypes arise, and found Int6 did not appear to be
required for the specification or organization of premigratory and
migrating cartilage precursors (Figure S2). In contrast, alcian blue
cartilage staining revealed a specific loss of the five ceratobranchial
cartilage elements in the int6 morphants, whereas Meckel’s,
palatoquadrate, and hyoid cartilage were all present, albeit
misshapen (5.5 dpf int6 MO n=45/53; con MO n=1/34;
Figure 1I–L, Figure S3). Expression of int6 mRNA restored
normal craniofacial elements to the int6 morphant (data not shown);
and the int6
hi2470 mutant had an almost identical craniofacial
phenotype (Figure 1M, N) indicating a genuine requirement for
Int6 in craniofacial development.
Loss of Int6 alters MEK protein and Erk signaling
Biochemical evidence in fission yeast suggests that Int6 is part of
a specialized eIF3 translation initiation complex that may target
specific mRNAs for translation [21]. Given the involvement of
INT6 in cell proliferation [16], western blots using a panel of
antibodies against proteins involved in the cell cycle and associated
signalling pathways were performed using lysates from control and
INT6 siRNA transfected MDA-MB-231 cells. Of 16 proteins
investigated in this way, only MEK1 levels were altered by INT6
siRNA transfection (Figure 2). As previously reported [20], we
found INT6-siRNA cell lysates had reduced levels of INT6 protein
compared with the untransfected and reverse INT6-siRNA
sequence. We also found a dramatic reduction of MEK1 protein
Figure 1. Int6 is essential for zebrafish embryonic development. (A)
Western blot analysis of Int6 (*) in zebrafish embryos injected with
a control (con) MO or int6 MO. (B) int6 morphant melanocytes are less
darkly pigmented. (C–F) Int6 is required for pigment cell placement in
the tail, as int6 morphants and int6
hi2470 mutants have misplaced
pigment cells in the tail fin (D, arrow). Ambient light illuminates the
iridophore ‘star-light’ pattern seen in the int6
hi2470 embryos (F, arrow).
(G–H) By 5 dpf, embryos injected with a con MO have clearly visible
certobranical arches, while int6 morphants do not have visible
certobranical arches, in addition to other abnormalities, including
unconsumed yolk sac, heart and eye development. (I–N). Alcian blue
staining of 5 dpf embryos shows loss of ceratobrancial arches 1 through
5. M, Meckel’s; PQ, palatoquadrate; CH, ceratohyal; CB, ceratobrancial.
doi:10.1371/journal.pone.0000959.g001
Figure 2. INT6 is required for MEK protein levels and Erk-signaling. A. Osteosarcoma U2-OS cells untransfected (U), or transfected with siRNA
targeted against the INT6 mRNA (si) or the reverse sequence (R), show reduced levels of INT6 and MEK1 protein specifically after transfection with
INT6-siRNA, but no reduction in BAX, tubulin or actin protein levels. (B) Semi-quantitative-PCR shows MEK1 mRNA is unaffected in reverse sequence
and INT6-siRNA treated cells, coupled with the expected reduced levels of the INT6 message in the INT6-siRNA transfected cells. c, PCR control
without DNA. (C) Phospho-Erk levels are reduced in int6 morphants, while ponceau stain detects equal loading of protein on the gel.
doi:10.1371/journal.pone.0000959.g002
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actin protein levels appeared unaffected in the INT6-siRNA
transfectedcells(Figure2A).ThelossofMEK1wasspecificallyatthe
protein level, as semi-quantitative-PCR showed normal levels of
MEK1 mRNA in INT6-siRNA treated cells, as well as the expected
reduced levels of the INT6 message in the INT6-siRNA transfected
cells (Figure 2B). The possibility that INT6 may affect MAPK
signaling through control of MEK protein levels prompted us to
examine the phosphorylation state of Erk1/2, downstream targets of
the Mek kinases, in int6 morphant zebrafish embryos. Compared
with control MO embryos, int6 morphant embryo lysates had
reduced phospho-Erk levels (Figure 2C). These data suggest a novel
function for Int6 in the control of MAPK signaling in the developing
embryo, possibly by direct control of MEK1 protein levels.
Int6 and Mek pathways converge during
development
If Int6 controls Mek activity in the developing embryo, we
theorized that specific developing tissues might have overlapping
expression domains of Int6 protein and phospho-Erk activity.
Indeed, immunohistochemistry with antibodies directed against
Int6 and phospho-Erk revealed overlapping domains of expression
in the developing craniofacial region in 3 and 4 dpf embryos
(Figure 3A–F). Strong Int6 tissue-specific expression was also
detected in the developing intestine and lens, regions that had little
or no phospho-Erk expression (Figure S4). Given the observed
phospho-Erk and Int6 expression in the craniofacial region, we
hypothesized that some of the Int6 phenotypes, such as the jaw
formation defect, might be phenocopied by repression of Erk
signaling. As interpretation of MO phenotypes has recently been
complicated by the identification of MO-induced p53-dependent
craniofacial defects [22], we used an alternative approach – the
highly selective, clinically active MEK inhibitor CI-1040 [23] – to
reduce Mek signaling in zebrafish. We added the drug at 4 hpf at
a concentration of 0.25, 0.5, and 1.0 mM, and confirmed loss of
phospho-Erk expression by Western blot analysis (data not shown).
Notably, the addition of CI-1040 caused a dose-dependent loss of
the posterior structures of the embryo, such that 1.0 mM CI-1040
caused a severe anterior-posterior (AP) axis defect (Figure 4A–C),
consistent with a role for FGF signaling in the development of the
AP axis [24]. CI-1040 also caused loss of ceratobranchial cartilage
elements, while the anterior elements – Meckel’s, palatoquadrate
and hyoid cartilages – were present but misshapen (Figure 3G–J),
similar to the effects seen in int6 morphants and mutants.
To further elucidate the biological relevance of Int6 and Mek
signaling, we took advantage of the ease with which signaling
pathways can be altered pharmacologically in specific genetic
contexts in the zebrafish system. We reasoned that if Int6
contributes to activation of Mek signaling, then embryos with
reduced Int6 should be hypersensitive to low doses of the MEK
inhibitor CI-1040. In control embryos treated with 0.25 mM CI-
1040, no changes in the anterior-posterior axis were detected
(Figure 4B). In addition, int6 morphants generated by low doses of
MO (0.25 ng) did not have an altered AP axis (Figure 4D). In
contrast, in combination with low doses of CI-1040, the low dose
int6 morphant showed a severely enhanced AP axis phenotype
(Figure 4E). Taken together, these data provide further evidence
that int6 may play a role in modulating MEK signaling in vivo.
DISCUSSION
Activated in most cancers, the MAPK signaling pathway is among
the most attractive targets for novel anti-cancer therapies [23].
Like MAPK signaling pathways, most of the Int pathways - Wnt,
Figure 3. Int6 and phospho-Erk expression in the developing zebrafish embryo, and pharmacological inhibition of Mek alters ceratobrancial
(CB) arches. (A–F). Immuno-histochemistry of Int6 and phospho-Erk in the developing craniofacial tissues, counter stained with hematoxylin, and
phospho-histone H3 to show cycling cells. (G, H) Ventral whole mount views of Alcian blue stained pharyngeal cartilages show loss of ceratobrancial
arches 1–5 and a reduction of Meckel’s (M), palatoquadrate (PQ) and ceratohyal (CH) cartilages in 4 dpf embryos treated with 0.5 uM CI-1040. (I, J)
Sections of 4 dpf embryos hematoxylin and eosin stained after 0.5 uM CI-1040 treatment reveals loss of CB arches 1–5 (brackets). E, Ethmoid plate; PC,
Parachordal cartilage.
doi:10.1371/journal.pone.0000959.g003
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frequently activated to promote oncogenesis. We provide evidence
that, like other Int gene products, Int6 is required for vertebrate
development (Figure 1), in part by providing a novel layer of
MAPK signal transduction regulation (Figure 2). With the wide
range of cellular activities attributed to INT6, the mechanistic
detail of this control remains to be understood; our early
investigations indicate reduction of MEK1 in INT6-siRNA treated
mammalian cells is not dependent on the proteasome (M.G. &
C.J.N., unpublished data), making direct MEK1 regulation by INT6-
dependent translation a possibility.
Recently, importance of RAS, RAF and MEK in human
disease has been extended beyond cancer by the discovery that
human germ-line mutations in these genes cause the LEOPARD-
Noonan family of syndromes [25]. Detailed immunohistochemical
studies in mice have identified highly regulated, specific domains
of discrete and dynamic ERK phosphorylation throughout
development, including the pharyngeal arches and limb buds
[26]. In the first Int6 protein expression studies in a whole
developing animal, we show that Int6 has regionally overlapping
domains of protein expression with phospho-Erk, primarily in the
craniofacial region (Figure 3, Figure S4). Lending biological
significance to these observations, we show that phenotypic
characteristics are shared between the loss of Int6 and inhibition
of Mek activity (Figure 3). In addition, partial loss of Int6 causes
embryos to be highly sensitive to a mildly compromising dose of
Mek inhibition, revealing an in vivo interaction between Int6
protein expression and developmental Mek-Erk signaling
(Figure 4). As early over-expression of Ras-Raf-Mek signaling
causes morphologic defects, we are currently generating transgenic
lines that allow temporal control of Mek signaling, which will be
a valuable tool for deeper genetic dissection of the Int6-Mek-Erk
relationship in vivo. It will be critical in future studies to establish if
Int6 is capable of controlling both Mek1 and Mek2; our initial
MO studies indicate that MEK2 may have a specific role in
melanocyte migration (C.A. & E.E.P, unpublished data), raising the
possibility that the pigment cell migration defects observed in the
int6 morphants also reflect altered MEK signaling.
FGF signaling is crucial for skeletal development, exemplified by
the mutations that disrupt FGF signaling in human genetic skeletal
abnormality syndromes [27]. In the developing mouse embryo,
most phospho-ERK domains overlap with FGF signaling domains
[26]. FGF signaling molecules are candidates for upstream
activation of the Int6-moderated Mek-Erk signaling that shapes
the craniofacial skeleton in vertebrates [28,29], and candidate
downstream targets of Int6-Mek-Erk signaling include the
chondrocyte differentiation transcription factor Sox9, which
requires Mek activity for transcriptional activity [30]. We also
note that erk2, but not erk1, is specifically expressed in the
pharyngeal arches in two-day old zebrafish embryos [31], possibly
suggesting that Int6-Mek modulation in the developing craniofa-
cial region may specifically signal through targets of Erk2.
Relating the Int6 modulation of Mek-Erk signaling to cancer
developmentisanew angleforfutureinvestigation.Onepossibilityis
that in MMTV induced mammary tumors, the truncated Int-6
protein may act as an oncogene by altering MEK-ERK signaling.
Weproposethat the diverse cellularlocations ofInt6, combined with
the temporal expression and localization of Mek1/2 and Erk1/2,
may result in fine-tuning of Mek-Erk signaling pathways in specific
tissues during development, and may have important implications
for the role of INT6 in tumorigenesis.
METHODS
Zebrafish husbandry and morpholino studies
Zerbafish (Danio rerio) lines AB, AB*, and AB*-TPL were raised
and staged as described [32,33]. MOs (Table 1) were designed by
and purchased from Gene Tools, LLC (USA), and 1 ng injected
into one-cell stage embryos.
Phenotype analysis
Phenotype analysis were performed as described: cell cycle studies
[34]; alcian blue staining [35]; probe synthesis and whole-mount
in-situ hybridizations [36]. cDNA probes for neural crest markers
Figure 4. Int6 and Mek signaling interact in vivo. (A–C). Only embryos treated with the 1.0 mM CI-1040, and not 0.25 mM, show a loss of posterior
structures, in contrast to (D) int6 morphants (int6 MO 0.25 ng). (E, F) In combination with 0.25 mM of CI-1040, 0.25 mgo fint6 MO causes a dramatic
alteration of the anterior-posterior axis.
doi:10.1371/journal.pone.0000959.g004
Table 1. Oligonucleotides used in this study
......................................................................
Method Symbol Oligonucleotide
Morpholino
Control con MO 59 CCTCTTACCTCAGTTACAATTTATA
int6 Translation block int-6 MO 59 GGTCAGATCGTACTCCGCCATGATG
int6 5-base pair
mismatch
int-6 5MM 59 GGTgAGATCcTAgTCCGCgATcATG
siRNA
INT6 sense siRNA (si) INT6-siRNA 59 GAACCACAGUGGUUGCACAUU
INT6 reverse siRNA (R) R 59 UUACACGUUGGUGACACCAAG
RT-PCR primers
MEK1 forward 59 ATTATTGTTCCCCTAAGTGGATTG
MEK1 reverse 59 TTACAACAGCATTGGTACTTGGAT
INT6 forward 59 ATGGCGGAGTACGACTTGACT
INT6 reverse 59 TCAGTAGAAGCCAGAATCTTGAGT
Actin forward 59 CGTGATGGTGGGCATGGGTCA
Actin reverse 59 CTTAATGTCACGCACGATTTCC
doi:10.1371/journal.pone.0000959.t001
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USA). Polyadenylated int6 mRNA was generated using Ambion
mMessage mMachine (#1340).
Cell culture and RT-PCR analysis
MDA-MB-231 cells were grown and transfected as described [19]
using Lipofectamine (Invitrogen) with si-oligonucleotides (Table 1;
Eurogentec) at a final concentration of 100 nM in Optimem
(Gibco). Forty-eight hours after transfection total RNA was
isolated (RNeasy Mini Kit; Qiagen) and one-step RT-PCR
reactions (Qiagen) accomplished using specific primers (Table 1).
Immunoblotting
Whole-cell lysates and zebrafish extracts were generated [31,19]
and immunohistochemistry was performed as described [36].
Antibodies used as in Table 2.
SUPPORTING INFORMATION
Figure S1 Cell cycle analysis of int6 morphants. Whole-mount
immunohistochemistry with the late G2/M phase marker,
phospho-histone H3 shows only slightly reduced numbers of cells
in late G2/M phase in the int6 morphant compared to the control.
Similarly, DNA content as measured by flow cytometry reveals
only a slight reduction of cells in G2/M phase in the int6
morphant. Thus, we find that loss of Int6 in normal vertebrate
cells (as well as in additional human cancer cell lines, M.G. &
C.J.N. unpublished data) does not appear result in an accumu-
lation of cells in G2/M progression.
Found at: doi:10.1371/journal.pone.0000959.s001 (4.75 MB TIF)
Figure S2 Lateral views of in situ hybridization of neural crest
markers in control and int6 morphants, revealing no change in cell
number or migration as indicated by the apparently normal
expression of dlx2 (stages 6–36 hpf, examined at two hour intervals),
nor of early markers of NCC and melanocytes, such as sox10,
crestin, snail and mitfa (24 hpf) in int6 morphants. These
observations were extended by examination of a transgenic sox10-
GFP line (1) revealing unaltered GFP-expressing NC-derived cells in
int6 morphants within the first 48 hpf, but a loss of GFP expressing
differentiated pharyngeal arches 3–7 by 3 dpf (data not shown).
Found at: doi:10.1371/journal.pone.0000959.s002 (40.41 MB
TIF)
Figure S3 Development of the pharyngeal arches in the
developing control (A–C) and (D–F) int6 morphant animals. Note
the loss of pharyngeal arches (A, bracket) in the int6 morphants
(bracket). Sections were stained with methylene blue. Anterior to
the left.
Found at: doi:10.1371/journal.pone.0000959.s003 (14.09 MB
TIF)
Figure S4 Immunohistochemistry of Int6 and phospho-Erk
staining in 4 dpf embryos. (A, B) While Int6 and phospho-Erk
signaling overlap in the craniofacial region, they also have distinct
patterns, for example in the eye and (C, D) gut. We note that while
Int6 and phospho-Erk have overlapping domains of expression in
the craniofacial region, Int6 staining in the craniofacial region was
stronger than phospho-Erk, and phospho-Erk staining was limited
to specific tissues within the craniofacial region. M, Meckel’s; E:
Ethmoid plate; CH, ceratohyal; CB, ceratobrancial. Sagittal
section, anterior to the left.
Found at: doi:10.1371/journal.pone.0000959.s004 (17.60 MB
TIF)
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